Literature DB >> 1917156

Abnormalities of the EGF receptor system in human thyroid neoplasia.

N R Lemoine1, C M Hughes, W J Gullick, C L Brown, D Wynford-Thomas.   

Abstract

The epidermal-growth-factor receptor (EGF-r) and its ligands are involved in the control of proliferation of both normal and neoplastic thyroid epithelium. Autocrine stimulation of growth involving this receptor system has been identified in several types of human neoplasia and we were interested to determine whether it might occur in human thyroid tumours. We have therefore examined an archival series of thyroid tumours and non-neoplastic pathologies for expression of the EGF-r and 2 of its ligands, transforming growth factor alpha (TGF-alpha) and epidermal growth factor (EGF), using immunohistochemistry. We found evidence of expression of both the EGF-r and the TGF-alpha in the majority of thyroid tumours, with a trend to higher expression in more malignant neoplasms. We also found variable levels of expression of EGF-r and TGF-alpha in all cases of thyroiditis examined. We conclude that there is a potential autocrine loop involving the EGF-r system in both neoplastic and non-neoplastic conditions of the human thyroid.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1917156     DOI: 10.1002/ijc.2910490414

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.

Authors:  Z Lu; G Jiang; P Blume-Jensen; T Hunter
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

3.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

4.  Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44.

Authors:  M Zhang; R K Singh; M H Wang; A Wells; G P Siegal
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

5.  Tumor spheroid invasion in epidermal growth factor gradients revealed by a 3D microfluidic device.

Authors:  Young Joon Suh; Mrinal Pandey; Jeffrey E Segall; Mingming Wu
Journal:  Phys Biol       Date:  2022-03-10       Impact factor: 2.583

6.  Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies.

Authors:  B Saller; G Stapfer; B Bein; R Hoermann; F Spelsberg; K Mann
Journal:  Clin Investig       Date:  1993-11

7.  Molecular cloning and tissue distribution of pig transforming growth factor alpha.

Authors:  T J Vaughan; P S James; J C Pascall; K D Brown
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

8.  RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Authors:  Michelle Croyle; Nagako Akeno; Jeffrey A Knauf; Doriano Fabbro; Xu Chen; Jacqueline E Baumgartner; Heidi A Lane; James A Fagin
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Epidermal growth factor receptor structural alterations in gastric cancer.

Authors:  Cátia Moutinho; Ana R Mateus; Fernanda Milanezi; Fátima Carneiro; Raquel Seruca; Gianpaolo Suriano
Journal:  BMC Cancer       Date:  2008-01-16       Impact factor: 4.430

10.  Prognostic impact of EGF-receptor in papillary thyroid carcinoma.

Authors:  L A Akslen; A O Myking; H Salvesen; J E Varhaug
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.